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THE effect of L-carnitine and some of its acyl derivatives
on serum TNF production and lethality in a murine
experimental endotoxin shock model was investigated. In
some instances, serum IL-6 production was also evaluated.
In this experimental model, C57BL/6 mice received
30 mg/kg LPS (E. cell 055:B5) injected intraperitoneally,
while L-carnitine and its derivatives were administered
according to different schedules. Serum levels ofTNF and
IL-6 were evaluated I h following LPS injection. The
treated animals were also monitored daily for differences
in body temperature, feeding, and survival for 10 days after
LPS injection. Although some derivatives were able to
significantly affect TNF production, the marked decrease
in serum TNF levels of LPS-treated mice was not
paralleled by a substantial increase in survival.
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Introduction
Septic shock is a clinical syndrome associated
with a high lethality rate, and characterized by
various haemodynamic and immuno-biochemical
alterations. This disease is primarily caused by
Gram-negative bacteria, but it may also be
consequent to infections by some Gram-positive
bacteria, fungi, and probably parasites and viruses.
2
The pathophysiological effects caused by Gram-
negative bacteria have been ascribed to lipopoly-
saccharide (LPS) a component of the bacterial outer
membrane, which has also been termed endotoxin
because of its toxic effects.
3 LPS causes septic shock
by interacting with various components of the
host’s immune system, and primarily with macro-
phages, which in turn release several endogenous
mediators that are themselves the ultimate effectors
of the disease.
4-6 Recently, the systemic release of
large amounts of various cytokines has been
associated with fatal outcome in human septic
shock. 7,8
TNF is one of the cytokines considered to play
a pivotal role as a mediator of the host’s response
to LPS. Therefore, blocking or antagonizing TNF
in sepsis may have therapeutic potential. Further-
more, making TNF a target for intervention, rather
than LPS, may be more advantageous in that TNF
has also been found to be involved in the
pathogenesis of shock due to Gram-positive
bacteria. 1’11 Among the drugs used in giving
metabolic support to septic patients, t-carnitine has
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been found to be a fairly good candidate to
ameliorate the host’s metabolic response to ep{ic
12-14 processes.
L-Carnitine is a drug that is not only essential for
the mitochondrial oxidation of long-chain fatty
acids, but also for intercompartmental shuttling of
energy substrates as well as elimination of toxic
metabolites, and modulation of the free CoA/Acyl-
CoA ratio, is Although the information concerning
the effects of carnitine on cells of the immune
system is still scanty, a report showed that
L-carnitine effectively inhibited chemiluminescence
in PMA-stimulated human PMN leukocytes.
16 This
is of some interest in the light of the findings that
both chemiluminescence as well as TNF production
are phenomena negatively regulated by cyclic
nucleotides. 17’18 In this report the authors invest-
igated the effect of L-carnitine and some of its acyl
derivatives on endotoxin-induced serum TNF
production, lethality, and some physiological
responses (feeding and body temperature) in a
murine experimental endotoxin shock model.
Experimental endotoxaemia has become a
valuable experimental model for septicaemia in
laboratory animals. Although this model does not
completely reproduce all the features of clinical
septic shock, the accumulated evidence shows that
it reliably mimics Gram-negative sepsis.
3 Another
cytokine, IL-6, has recently been implicated in the
pathophysiology of septic shock,
9 and a report has
also shown that it may play a role in endotoxin
treated mice.2 In some instances, therefore, the
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effects of L-carnitine on serum IL-6 levels in our
model of endotoxin shock were also evaluated.
Materials and Methods
Animals: Male C57BL/6 mice were purchased from
Iffa-Credo (Lyon, France). Mice (6-7 weeks of age
at the time of use) were housed in groups of eight,
and were allowed food and water ad libitum. They
were kept under specific pathogen-free conditions,
and were randomly assigned to various treatment
groups.
Drugs and chemicals: L-Carnitine as well as its
derivatives were all synthesized by Sigma-Tau
Chemical Laboratories (Pomezia, Italy). LPS
(Escherichia coli 055:B5) was from Difco (Difco
Laboratories, Detroit, MI, USA); actinomycin
D-mannitol was from Sigma (Sigma Chemical
Laboratories, St Louis, MO, USA). Recombinant
murine TNF and recombinant murine IL-6 were
both purchased from Genzyme (Boston, MA,
USA). All chemicals were dissolved in pyrogen-free
physiological saline solution just prior to use.
Tritiated thymidine (3H-TdR, 5 Ci/mmol) was from
Amersham (Aylesbury, Buckinghamshire, UK).
Cell lines and tissue culture media: The TNF-sensitive
L929 cell line (a murine fibrosarcoma) was grown
in RPMI-1640 medium containing 25 mM HEPES
and 2 mM L-glutamine (Biochrom KG, Berlin,
Germany) supplemented with 10% heat-inactivated
Myoclone foetal calf serum (FCS) (Gibco, Grand
Island, NY, USA), and 50/ig/ml gentamicin
(Sigma). The murine hybridoma cell line B9, which
is dependent on IL-6 for growth
21 was maintained
in the above culture medium with the further
addition of 5.0 x 10 -s M 2-mercaptoethanol
(Sigma) and 10 U/ml recombinant murine inter-
leukin 6 (rmIL-6).
Endotoxaemia model: C57BL/6 mice received 30 mg/kg
LPS intraperitoneally (i.p.), which had been
predetermined to produce approximately 60%
lethality. In the majority of experiments, animals
were first pre-treated i.p. with L-carnitine deriva-
tives 1 h before LPS injection, and then treated
intravenously (i.v.) 10 min following LPS admin-
istration. However, other treatment protocols were
also adopted, and they are reported in the relevant
tables. Some animal physiological responses to
endotoxaemia were graded such as food intake,
body weight, mobility, amount of ocular exudate,
and rectal temperature.
In particular, temperature measurements were
taken with an electronic thermometer (model
Babuc/M, 1.S.I., Milan, Italy) with the appropriate
thermistor (probe TM35S). Animal health state was
classified as follows: very ill (body temperature
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below 32C, absence of mobility, marked body
weight loss, abundant ocular exudate); fair (body
temperature between 32 and 35C, poor mobility,
small body weight loss, moderate ocular exudate);
normal (body temperature above 35C, normal
mobility, normal body weight, absence of ocular
exudate). All groups of animals were examined at
24 h intervals after LPS injection to assess survival,
and they were followed up to 10 days.
Serum TNF and IL-6 determinations: To determine
circulating TNF and IL-6 levels, ether-anaesthe-
tized mice were bled by retro-orbital sinus puncture
at 1 h following 30 mg/kg LPS injection. Blood was
allowed to clot at room temperature, and then
centrifuged at 1 000 x g for 15 min. The separated
serum was stocked and stored at -80C until
assayed.
TNF bio-assay: Concentrations of TNF in serum
were determined by using the L929 cytotoxicity
assay described by Flick and Gifford22 with minor
modifications. Briefly, 100/il of L929 cells
(3.2 x 105 cells/ml) in RPMI-1640 containing 10%
FCS were seeded into each well of a flat-bottomed
96-well microtitre plate (Falcon, Becton &
Dickinson, Meylan Cedex, France) and incubated
overnight at 37C in a humidified atmosphere of
5% COg. After incubation, spent medium was
discarded and two-fold serial dilutions (carried out
in RPMI-1640 1% FCS) of serum samples were
added to the cells in the presence of actinomycin
D-mannitol at a final concentration of 1 /lg/ml. The
L929 cell cultures were then further incubated for
18h. Following incubation, the medium was
discarded, and the plates were first washed twice
with 0.9% NaC1 and then stained for 15 min at room
temperature with 0.5% (w/v) Crystal Violet in 20%
ethanol and 8% formaldehyde. After discarding the
stain, the wells were gently washed in running tap
water; the dye which had been taken up was eluted
with 33% acetic acid and the relative absorbance at
540 nm was measured with a Multiskan MCC/340
ELISA reader (Flow Laboratories, Mclean, VA,
USA). TNF activity is expressed in units/ml, and is
defined as the reciprocal of the dilution necessary
to cause death of 50% of the actinomycin-treated
control cells. Final TNF concentrations for each
sample were calculated by interpolating the values
of four to six sample dilutions.
IL-6 bio-assay: Levels of IL-6 in serum were
measured by its ability to induce proliferation of
the murine B-cell hybridoma line B9.
21 B9 cells were
washed twice prior to use in the assay in order to
remove the exogenous rmIL-6 added to sustain
their growth.
Briefly, two-fold serial dilutions of thawed sera
in RPMI-1640 supplemented with 10% FCS,LPS-induced TNF production
5.0 x 10-5M 2-mercaptoethanol were added to
flat-bottomed 96-well microtitre plates containing
5.0 x 103 cells per well. Cells were then incubated
for 96 h at 37C in a humidified atmosphere of 5%
CO2, and pulsed with 0.5/Ci/well of 3H-TdR
during the last 18 h of incubation. Afterwards, the
cells were harvested onto glass fibre filtermats
(Pharmacia, Turku, Finland) by using an automated
cell harvester (Pharmacia), and 3H-TdR incorpora-
tion (an index of cell proliferation) was assessed by a
/g-plate counter (Pharmacia). IL-6 activity is
expressed in B9 hybridoma growth units per ml,
and one unit is defined as the reciprocal of the
sample dilution required to produce one half-
maximal proliferation. Values for each sample were
calculated by interpolating the sample cpm of four
to six dilutions by means of linear regression
analysis.
Statistical analysis: Statistical analysis ofTNF and IL-6
values was performed by using the Student’s t-test,
while survival data were assessed by Fisher’s exact
test.
Results
Physiological responses to endotoxin: LPS intraperitoneal
injection in C57BL/6 mice (30 mg/kg body weight)
provoked a considerable serum TNF release (Fig.
1). Systemic TNF secretion started as early as 0.5 h
after LPS administration reaching a peak at I h, and
then declined to undetectable levels within the next
4 h. Twenty-four hours following LPS challenge,
animals exhibited decreased body weights paralleled
by concomitant hypothermia, which lasted up to
3 days before they started to recover (Fig. 2).
Furthermore, the animals given endotoxin showed
an abundant ocular exudate, a dramatic decrease
in food intake as well as a loss of mobility and,
when touched, a comatose-dazed behaviour.
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FIG.1. Time course of serum TNF concentration after i.p. administration
of 30 mg/kg LPS to C57BL/6 mice. TNF was determined as detailed in
Materials and Methods. Values are mean (four animals per group)-I-
standard deviation.
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FIG.2. Variations in body temperature (squares) and body weight
(circles) in control (open symbols) and LPS-challenged mice (closed
symbols). Animals were checked up to I0 days after LPS administration
at day 0 (30 mg/kg, i.p.).
L-carnitine and one derivative: L-Carnitine (ST 198)
caused a marked decrease in serum TNF levels and,
at the same time, induced an increased serum IL-6
release. The observed variation in TNF and IL-6
levels was statistically significant (p < 0.05), and
was confirmed by a second experiment performed
according to the same experimental protocol.
Although L-carnitine significantly affected serum
TNF and IL-6 release, it became clear that, at least
at the doses employed in our protocol, it was not
able to confer a significant protection upon the
animals. In fact, only a small improvement in
survival was observed, namely ten survivors in the
ST 198-treated group vs. eight survivors in the LPS
control. Similar results were obtained even with a
protocol based on repeated L-carnitine administra-
tions. The ST 784 derivative exerted similar effects
both on serum TNF levels and survival, but, at
variance with L-carnitine, was unable to modulate
IL-6 release (Table 1). Although the survival was
not significantly increased after treatment with ST
198 and ST 784, it was found that both compounds
markedly improved the health conditions of
LPS-challenged mice as evaluated by food intake.
The former compound, in particular, appeared to
be more active in being able to induce a three-fold
increase of food consumption with respect to the
LPS control (Table 2).
Acetyl-L-carnitine and three derivatives: At the doses
utilized throughout the experiments, neither
acetyl-L-carnitine (ST 200) nor its derivatives were
able to significantly modulate serum TNF release
and survival, except ST 1025 which, although
unable to affect the animal survival, was still capable
of inducing a significant reduction (p < 0.001;
p < 0.01) in TNF levels in two different experi-
ments. The lack of effects of ST 200 and ST 1025
on animal survival was also confirmed when both
compounds were administered using the protocol
based on multiple administrations. Interestingly, all
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Table 1. Effects of L-carnitine (ST 198) and its derivative (ST 784) on both serum TNF and IL-6 production, and
lethality of mice challenged with LPS
TNF IL-6
Lethality
% No. % No.
Compound Treatment variation of mice p variation of mice p Dead/total
ST 198 (50 mg/kg) -57 8 <0.05 + 124 8 <0.05 14/24 (16/24)
(50 mg/kg) -64 8 <0.05 + 39 8 <0.05
2 (50 mg/kg) 6/10 (8/10)
ST 784 (50 mg/kg) -36 24 <0.02 +19 8 n.s. 9/16 (11/16)
2 (50 mg/kg) 7/10 (8/10)
Treatments were performed by injecting LPS 30 mg/kg i.p. at time zero and administering the compounds, at the dose indicated,
as follows: 1) -60 min i.p. and + 10 min i.v., 2) from day to day + 3 i.p. twice a day (once at day 0). Statistical significance
(p) was evaluated by the Student’s t-test. Lethality of the 1-PS-treated group is indicated in brackets. ST 198 L-carnitine inner
salt; ST 784 L-carnitine chloride ester with fl-hydroxybutyric acid.
Table 2. Health conditions, evaluated by food intake of
LPS-challenged mice following treatment with ST 198 and ST
784
Compound
Food Cumulative Food consumed per
consumed survival animal per day
(g) (d) of survival
Untreated control 311 100 3.11
LPS control 51 40 1.28
ST 198 158 53 2.98
ST 784 105 49 2.14
Mice (ten animals per group) were treated with ST 198 (50
mg/kg, i.p.) and with ST 784 (50 mg/kg, i.p.), twice daily but
once at day 0, starting from day -1 to day + 3, with respect to
the LPS challenge (day 0). Control groups were either injected
with 30 mg/kg LPS (LPS control) or treated twice a day with
saline from day through day + 3 (untreated control). Animals
were followed up to 10 d after LPS injection. Food consumed
during this time as well as cumulative survival (referred to as the
sum of the days of survival of each single mouse within a group)
were evaluated. The ratio of the former and the latter parameter
yields the food consumed per animal per day of survival
(right-end column).
the compounds belonging to this class caused a
significant increase in serum IL-6 release (Table 3).
PropionyLL-carnitine and three derivatives" Although
propionyl-L-carnitine (ST 261) and its derivatives
were all able to decrease serum TNF levels, their
effect was not statistically significant. The only
exception was ST 780, which lowered < 0.02)
serum TNF release when the treatment schedule
included an i.v. administration. No significant
changes in serum IL-6 levels were observed in
LPS-treated mice following administration with ST
261 and ST 780. All compounds belonging to this
class were unable to reduce the LPS-induced
lethality, at least at the doses utilized in the
experiments (Table 4).
IsobutyryLL-carnitine and two derivatives: Even though
the parent compound (ST 284) was not able to
influence serum TNF release, its derivatives ST 730
Table 3. Effects of acetyI-L-carnitine chloride (ST 200) and its derivatives (ST 857, ST 943, ST 1025) on both serum TNF and
11_-6 production, and lethality of mice challenged with 1_PS
TNF IL-6
Lethality
% No. % No.
Compound Treatment variation of mice p variation of mice p Dead/total
ST 200 (50 mg/kg) -26 8 n.s. +61 8 <0.01 9/16 (10/16)
(50 mg/kg) -52 8 n.s. +20 8 <0.02
2 (50 mg/kg) 7/10 (8/10)
ST 857 (50 mg/kg) -11 16 n.s. +45 8 <0.01 10/16 (9/16)
ST 943 (50 mg/kg) +24 8 n.s. +105 8 <0.001 13/16 (10/16)
(50 mg/kg) + 5 16 n.s.
ST 1025 (15 mg/kg) -60 16 <0.001 +73 8 <0.001 11/16 (10/16)
(15 mg/kg) -74 8 <0.01
2 (15 mg/kg) 7/10 (8/10)
Treatments were performed by injecting LPS 30 mg/kg i.p. at time zero and administering the compounds, at the dose indicated,
as follows: 1) -60 min i.p. and + 10 min i.v., 2) from day to day + 3 i.p. twice a day (once at day 0). Statistical significance
(p) was evaluated by the Student’s t-test. Lethality of the LPS-treated group is indicated in brackets. ST 200 acetyl-L-carnitine
chloride; ST 857 acetyl-L-carnitine chloride amide with arginine hydrochloride; ST 943 acetyl-L-carnitine tartrate acid ester
with -hydroxybutyric acid; ST 1025 acetyl-L-carnitine amide with citrulline.
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Table 4. Effects of propionyI-L-carnitine chloride (ST 261 and its derivatives (ST 780, ST 880, ST 921 on both serum TNF and
L-6 production, and lethality of mice challenged with LPS
TNF IL-6
Lethality
% No. % No.
Compound Treatment variation of mice p variation of mice p Dead/total
ST 261 (50 mg/kg) -37 8 n.s. + 8 n.s. 5/8 (6/7)
(50 mg/kg) -48 8 n.s. -2 8 n.s.
ST 780 (50 mg/kg) -62 8 <0.02 +8 8 n.s. 3/8 (1/8)
3 (50 mg/kg) 30 5 n.s. + 6 5 n.s.
2 (50 mg/kg) 5/8 (5/8)
ST 880 (50 mg/kg) -51 8 n.s. 6/7 (5/7)
ST 921 (50 mg/kg) -47 8 n.s. 6/8 (6/7)
Treatments were performed by injecting LPS 30 mg/kg i.p. at time zero and administering the compounds, at the dose indicated,
as follows: 1) -60 min i.p. and +10 min i.v., 2) from day -1 to day +3 i.p. twice a day (once at day 0); 3) -60 min i.p. and
+ 10 i.p. Statistical significance (p) was evaluated by the Student’s t-test. Lethality of the LPS-treated group is indicated in brackets.
ST 261 =propionyl-L-carnitine chloride; ST 780=propionyl-L-carnitine chloride ester with /-hydroxybutyric acid; ST
880 propionyl-L-carnitine chloride ester with -hydroxybutyric acid; ST 921 propionyl-L-carnitine chloride amide with arginine
hydrochloride.
and ST 878 significantly reduced (p < 0.05) TNF
levels. No differences in serum IL-6 levels were
found in mice intoxicated with LPS and treated
with ST 284 and ST 878. The survival of
LPS-challenged mice was not improved following
administration of any of these compounds (Table
5).
Isovaleryl-L-carnitine and six derivatives: Among the
compounds belonging to this class, only two
derivatives, namely ST 687 and ST 1037, were
effective in significantly reducing (p < 0.05) serum
TNF levels (Table 6). Even if none of the
investigated compounds significantly improved the
survival of the LPS-challenged mice, isovaleryl-L-
carnitine (ST 551) administration still allowed a
better recovery of health conditions of survived
mice. The class distributions of the animal health
state, based on animal body temperature and
evaluated at different days after treatment, are
shown in Fig. 3.
Discussion
Septic shock is an increasingly serious health
problem in hospitals, especially in intensive care
units, despite the use of multiple antibiotics,
surgical drainage, and intervention including
vasopressor and metabolic support. It was esti-
mated that this disease causes 100000 deaths
annually in the United States.
23 It is generally
accepted that the primary mediator of the
pathophysiological changes occurring in Gram-
negative sepsis is LPS, which in turn stimulates host
macrophages to produce a cascade of endogenous
mediators responsible for many alterations in host
physiology. There are many reports showing that
Table 5. Effects of isobutyryI-L-carnitine (ST 284) and its derivatives (ST 730, ST 878) on both serum TNF and IL-6 production,
and lethality of mice challenged with LPS
TNF IL-6
Lethality
% No. % No.
Compound Treatment variation of mice p variation of mice p Dead/total
ST 284 (50 mg/kg) -6 16 n.s. + 12 8
ST 730 (50 mg/kg) -51 7 <0.05
2 (50 mg/kg)
ST 878 (50 mg/kg) -51 8 <0.05 -23 8
2 (50 mg/kg)
n.s. 6/8 (3/8)
5/8 (6/8)
2/8 (3/8)
Treatments were performed by injecting LPS 30 mg/kg i.p. at time zero and administering the compounds, at the dose indicated,
as follows: 1) -60 min i.p. and + 10 min i.v., 2) from day to day + 3 i.p. twice a day (once at day 0). Statistical significance
(p) was evaluated by the Student’s t-test. Lethality of the LPS-treated group is indicated in brackets. ST 284 isobutyryl-L-carnitine
chloride; ST 730 isobutyryl-L-carnitine chloride ester with /Y-hydroxybutyric acid; ST 878 isobutyryl-L-carnitine ester with
y-hydroxybutyric acid.
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Table 6. Effects of isovaleryI-L-carnitine chloride (ST 551 and its derivative (ST 743, ST 687, ST
994, ST 803, ST 899, ST 1037) on serum TNF production, and lethality of mice challenged with LPS
TNF
Lethality
% No.
Compound Treatment variation of mice p Dead/total
ST 551 (50 mg/kg) -25 16 n.s. 11/24 (14/24)
ST 743 (50 mg/kg) -23 8 n.s. 6/8 (6/8)
ST 687 (50 mg/kg) -44 8 <0.05 5/8 (7/8)
2 (200 mg/kg) 8/8 (4/8)
ST 944 (50 mg/kg) +29 8 n.s. 5/8 (7/8)
ST 803 (5 mg/kg i.p. + 16 8 n.s. 8/8 (4/8)
and
mg/kg i.v.)
4 (5 mg/kg) 3/5 (5/7)
ST 899 (5 mg/kg) -27 8 n.s. 6/8 (6/8)
ST 1037 (5 mg/kg i.p. -44 8 <0.05 5/8 (5/8)
and
mg/kg i.v.)
Treatments were performed by injecting LPS 30 mg/kg i.p. at time zero and administering the
compounds, at the dose indicated, as follows: 1) -60 min i.p. and + 10 min i.v., 2) from day -1
to day + 3 i.p. twice a day (once at day 0); 4) -60 min i.p. Statistical significance (p) was evaluated
by the Student’s t-test. Lethality of the LPS-treated group is indicated in brackets. ST
551 isovaleryl-L-carnitine chloride; ST 743=isovaleryl-L-carnitine tartrate acid ester with
,-hydroxybutyric acid; ST 803=isovaleryl-L-carnitine bromide ester with Z-3-(6-chloro)-
phthalidiliden-ethanol; ST 899 isovaleryl-L-carnitine bromide ester with Z-3-(5-chloro)phthali-
diliden-ethanol; ST 1037 isovaleryl-L-carnitine chloride ester with dodecanol.
over-production of several cytokines such as IL-1,
IL-6, TNF, and IFN-2 is associated with severe
sepsis. Among these cytokines, however, TNF has
been shown to play a key role in many metabolic
derangements occurring during septic shock,
24 and
its abnormally high serum levels are often
correlated with poor prognosis.2s’26 Moreover,
TNF can also be found in the serum of animals
experimentally intoxicated with LPS and addition-
ally causes, when injected in animals, a toxic
syndrome indistinguishablegrom endotoxaemia.
2v-29
Experimentally induced endotoxin shock in labor-
atory animals, although it does not exactly
reproduce all the alterations of septic shock, has
become a valuable and very convenient model for
studying sepsis. In fact, it reliably mimics many
physiological as well as immunological dysregula-
tions occurring in this disease.24
By using this model, the authors found that LPS
injection in mice caused a dramatic reduction in
body temperature. This decrease was evident no
sooner than 24 h following LPS administration and
16
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FIG. 3. Health conditions, as evaluated by body temperature, at days +1, +4 and +10 of LPS-injected mice
treated either with saline (panel A) or with isovaleryl-L-carnitine (panel B) according to the treatment
protocol reported in Table 2. i, Dead; l, Very ill (<32C) I, Fair (32-35C) El, Survivors.
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lasted for two more days. During this time, the
LPS-injected mice were very sick, and they started
to recover only from the fourth day after LPS
challenge.
At variance with this finding, other investigators
reported an increase in body temperature in
different animal models’ as well as in humans2
following LPS injection. In agreement with our
results, however, Pogrebniak et a]. found that
C3H/HeN mice injected with LPS (30 mg/kg, i.p.)
were markedly hypothermic. Additionally, Handley
et al. 34 made similar observations in Balb/c mice
injected i.v. with 10mg/kg LPS. From these
studies, it can be argued that hypothermia is a
typical physiological response of mice to LPS and
appears to be independent of the strain used. In the
present model, moreover, smaller decreases in body
temperature were observed when lower doses of
LPS (down to 0.3 mg/kg) were employed, while a
dose as low as 0.03mg/kg was completely
ineffective (data not shown). Furthermore, the
decrease in body temperature was paralleled by a
concomitant body weight loss, which appeared to
be related to the dose of LPS (data not shown). The
maximum decrease of body weight was observed
48 h after LPS challenge, then the mice slowly
began to recover their normal weight. Taken
together, these data indicate that body temperature
and body weight are valuable parameters to
monitor health conditions of mice during en-
dotoxaemia. In a preliminary experiment, per-
formed to ascertain the time course of TNF
production, it was found that serum TNF peaked
as early as 1 h following LPS injection, and became
undetectable by 4 h. This result is consistent with
similar studies reported by other investigators in
different animal modelss- and in humans.2
In this experimental model L-carnitine and some
acyl derivatives were tested for possible protective
effects in LPS-challenged mice. A role of L-carnitine
in the treatment of sepsis was first suggested by
Border et al., who hypothesized that some septic
processes might be associated with an impairment
of lipid oxidation due to systemic depletion of
I-carnitine.
3u Support to this hypothesis was lent by
different investigators, who observed a significant
improvement in survival of LPS-challenged animals
following treatment with t-carnitine.39’4
In this LPS shock model, L-carnitine and its
derivative ST 784 were able to reduce serum TNF
levels, although this decrease was not always
statistically significant. Similarly, the compounds
derived from propionyl-L-carnitine and isobutyryl-
-carnitine were effective in reducing serum TNF
release in LPS-challenged mice. In contrast, only
two isovaleryl-L-carnitine derivatives, namely ST
687 and ST 1037, were found to significantly
decrease TNF levels. However, L-carnitine and
isovaleryl-t.-carnitine, which differently affected
serum TNF levels, were both able to improve
health conditions of LPS-injected mice and to
lightly reduce lethality as well. Different treatment
schedules and different dosages may be necessary to
ascertain the real therapeutic potential of these
compounds in counteracting LPS intoxication.
The authors found that serum TNF and IL-6
levels were modulated differently by treatment with
L-carnitines. In fact, in most cases where serum
TNF was significantly decreased, concomitant
significantly high levels of serum IL-6 were
observed. This is of interest in the light of the
suggestion that IL-6 may act as a negative
modulator of TNF production.’4 In addition,
IL-6 was found to induce hyporesponsiveness to
endotoxin in mice,
42 and to inhibit the release of
TNF in mice as well as in human U937 cells and
monocytes in vitro.4 Furthermore, it is known that
TNF and IL-6 synthesis is regulated differently by
various agents. High c-AMP levels, for example,
were reported to inhibit TNF synthesis while
inducing IL-6 production.
44-4s Additionally, Mar-
cinkiewicz
46 observed that the production of these
cytokines by murine peritoneal macrophages was
affected differently by prostaglandins PGE2 and
PGI2. In fact, while both prostaglandins inhibited
the release of TNF, they increased IL-6 production
at the same time.
It would be tempting to speculate, therefore, that
-carnitines might increase prostaglandin synthesis
and c-AMP levels, the latter either directly or via
prostaglandins, thereby decreasing TNF synthesis
and increasing IL-6 levels. IL-6 in turn would
further dampen the production of TNF.’4
Although additional investigations are needed,
reports showing that -carnitine and some of its
congeners were able to positively affect prostaglan-
dins release from macrophages
4 support this
hypothesis.
Although TNF release has been .reported to be a
prominent event during endotoxaemia,2’s’6’4 the
authors’ results also point out that TNF by itself
cannot be the only crucial mediator of lethality. In
fact, it was found that the significant reductions in
TNF levels brought about by several L-carnitine
derivatives were not correlated with a significant
reduction of lethality, though prolongation ofmean
survival time (data not shown) and ameliorated
health conditions of treated animals were observed.
The involvement of other critical factors in addition
to TNF is supported by several studies showing
that TNF by itself is necessary, although not
sufficient, to cause lethality during endotox-
aemia4,8,49,s0
Even though many questions concerning the
ultimate molecular mechanism of action of
t-carnitines in endotoxaemia are yet to be answered,
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it is envisaged that these compounds may be
helpful, when associated with conventional therapy,
in that they can effectively reduce TNF levels and
ameliorate the host’s metabolic processes. In
conclusion, these results would justify clinical trials
with L-carnitine in the treatment of sepsis. Indeed,
preliminary reports
12,51 indicate that early supple-
mentation of L-carnitine in the therapy of
septicaemia appears to counteract the onset of the
metabolic cascade leading to septic shock.
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